(Q35167477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Agnese Proietti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Laura Boldrini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gabriella Fontanini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

8

Alfredo Mussi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3

Cristiana Lupi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

7

Federico Davini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Antonio Chella

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Cristina Niccoli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

26 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

1537-1540

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib

3 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Targeting anaplastic lymphoma kinase in lung cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4356289

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25788996

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3892/OL.2015.2897

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

25788996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25788996%20AND%20SRC:MED&resulttype=core&format=json